Climb Bio, Inc. beat EPS estimates 64% of the time across 14 reported quarters (9 beats, 5 misses), averaging +1.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.22 | $-0.18 | +18.2% | Beat | |
| Q1 FY26 | $-0.26 | $-0.20 | +23.1% | Beat | |
| Q4 FY25 | $-0.20 | $-0.26 | -30.0% | Miss | |
| Q3 FY25 | $-0.16 | $-0.19 | -18.8% | Miss | |
| Q2 FY25 | $-0.19 | $-0.13 | +31.6% | Beat | |
| Q1 FY25 | $-0.15 | $-0.31 | -106.7% | Miss | |
| Q4 FY24 | $-0.15 | $-0.13 | +13.3% | Beat | |
| Q3 FY24 | not reported | $-0.13 | not reported | not reported | |
| Q2 FY24 | not reported | $-1.81 | not reported | not reported | |
| Q1 FY24 | not reported | $-0.06 | not reported | not reported | |
| Q3 FY23 | not reported | $-0.15 | not reported | not reported | |
| Q2 FY23 | not reported | $-0.19 | not reported | not reported |
Back to CLYM overview · CLYM holders · CLYM KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.